亚太传统医药2026，Vol.22Issue(2)：8-11,4.DOI:10.11954/ytctyy.202602002
天士力之骄专利组合分析及对中成药企业专利组合构建的启示
Analysis of Tasly-Zhijiao's Patent Portfolio and Its Implications for the Construction of Patent Portfolios by Traditional Chinese Medicinal Products Enterprises
摘要
Abstract
Objective:To investigate the patent portfolio of Tianjin Tasly ZhiJiao Pharmaceutica Co.,Ltd.,providing strategic references for traditional Chinese patent medicine(TCPM)enterprises in China.Methods:Patents were re-trieved from the PatSnap database using"Tianjin Tasly ZhiJiao Pharmaceutical Co.,Ltd."as the current applicant.Analysis encompassed:basic patent information,technology themes,substantive content,and portfolio sources.The patent strategy was further examined using Yiqi Fumai Injection as a case study.Results:132 patents were identified,including 130 invention patents(87%grant rate).Among granted inventions,79 were invalidated-primarily due to a nnuity non-payment(99%),with most maintaining validity for≥15 years.Technology themes were dominated by process patents.Portfolio sources included independent R&D and patent transfers,with protection focusing on TCPM formulations rather than Chinese materia medica.Conclusion:TCPM enterprises should increase invention patent rati-os,diversify patent types,enhance portfolio stability by linking formulations sharing identical active compositions,and expand portfolios through multifaceted approaches.关键词
中成药/专利组合/天士力之骄Key words
Chinese Patent Medicine/Patent Portfolio/Tasly-Zhijiao分类
医药卫生引用本文复制引用
甄思圆,刘扬,梁谦,李平,贺帆,李海燕..天士力之骄专利组合分析及对中成药企业专利组合构建的启示[J].亚太传统医药,2026,22(2):8-11,4.基金项目
首都卫生发展科研专项(首发2022-1-4291) （首发2022-1-4291）
中国中医科学院科技创新工程(CI2021A00501) （CI2021A00501）
